Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Equity Ratio (2016 - 2025)

Arcadia Biosciences' Equity Ratio history spans 12 years, with the latest figure at 0.63 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 37.37% year-over-year to 0.63; the TTM value through Dec 2025 reached 0.63, up 37.37%, while the annual FY2025 figure was 0.63, 37.37% up from the prior year.
  • Equity Ratio reached 0.63 in Q4 2025 per RKDA's latest filing, roughly flat from 0.63 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.78 in Q1 2022 to a low of 0.46 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.66, with a median of 0.66 recorded in 2023.
  • Peak YoY movement for Equity Ratio: skyrocketed 91.69% in 2021, then fell 29.58% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.71 in 2021, then grew by 1.73% to 0.72 in 2022, then decreased by 10.79% to 0.64 in 2023, then fell by 28.58% to 0.46 in 2024, then skyrocketed by 37.37% to 0.63 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Equity Ratio are 0.63 (Q4 2025), 0.63 (Q3 2025), and 0.58 (Q2 2025).